Introduction
============

Serious concerns about competing interests (CIs) in diabetes-related clinical practice guideline (CPG) development have recently been voiced in the medical literature ([@b6-jmdh-1-29]). Although CIs may take many forms, financial relationships of clinicians, scientists, and professional or disease-related organizations with industry have been the main focus of recent literature. In Canada, in the field of diabetes, the presence of undisclosed potential CIs of the authors of a CPG sponsored by the Canadian Diabetes Association was criticized in recent years ([@b6-jmdh-1-29]). The specific criticism ([@b6-jmdh-1-29]) stemmed from differences in recommendations on the use of a particular insulin formulation in the Canadian Diabetes Association (CDA) clinical practice guideline ([@b4-jmdh-1-29]), compared with those of a national drug formulary (Common Drug Review) ([@b3-jmdh-1-29]). The implication of the criticism was that undisclosed CIs of authors of the CDA guideline could potentially account for some of the differences in recommendations observed.

Relationships between industry and the authors of CPGs or specialty medical organizations are not uncommon, and may be under-reported. In a review of clinical guidelines published in six major medical journals in 1979, 1984, 1989, 1994, and 1999, only 3.7% of guidelines mentioned CIs ([@b9-jmdh-1-29]). Furthermore, in a cross-sectional survey of 192 authors of 44 CPGs endorsed by North American and European societies on common adult diseases published between 1991 and 1999, an average of 81% of authors per clinical practice guideline had interactions with industry and the average author interacted with 10.5 different companies ([@b5-jmdh-1-29]). In a survey of Australian medical organizations, 59% of organizations reported receiving support from one or more pharmaceutical companies ([@b8-jmdh-1-29]). In a review of 200 guidelines deposited in the US National Guideline Clearinghouse in 2004, investigators from the journal, *Nature*, found that 35% of authors disclosed a conflict of interest, 16% of authors helped write guidelines on illnesses relevant to companies in which they owned stock, and 49% of guidelines did not include any details of authors' CIs ([@b11-jmdh-1-29]). Moreover, an editor of the *Journal of the American Medical Association* has stated that, "drug company sponsors see guideline-issuing bodies as perfect places to exert influence" ([@b11-jmdh-1-29]). Such criticisms have led to questions such as "can we trust the evidence in evidence-based medicine?", pertaining specifically to evidence-based guideline development ([@b1-jmdh-1-29]).

Our aim was to assemble a multidisciplinary, multi-institutional, panel of experts, students, and lay people from across Canada to explore the issue of CIs in development and dissemination of CPGs, particularly focusing on diabetes care. The participants were identified as stakeholders in this issue, because of their clinical, academic, or methodologic focus, or because they acted as representatives of individuals with diabetes. Mixed methods, including qualitative and quantitative approaches were used in analyzing data that was collected.

Methods
=======

Format of the workshop and qualitative methodology
--------------------------------------------------

A half-day workshop was held in Toronto, Canada on October 18, 2006. We invited health, methodological, legal, and bioethical experts, trainees, and lay people from across Canada. Four structured lectures 20--30 minutes in duration were each followed by open discussion periods, moderated by two investigators (AMS and AG). The proceedings were audio recorded, with the exception of one lecture, as per the request of the speaker. The session was closed to the public. All participants were informed that their personal views would not be identified outside the group and open discussion was encouraged. When necessary, the discussions were refocused onto relevant concepts, with acknowledgement of the presence of some conflicting views.

An approach founded in Delphi methodology was used in developing summary statements ([@b7-jmdh-1-29]). A strict consensus was not the goal, given the sensitivity of the topic and the known conflicting views of some of the selected participants. A qualitative researcher (LM) and a research assistant took notes during the session, to supplement audio-recordings of the sessions. Relevant themes from the discussions and notes were extracted by the qualitative researcher (LM). The final theme summary statements were compiled by two of the investigators (LM and AS) using the data extracted by the qualitative researcher in her structured notes.

Survey several months after the workshop
----------------------------------------

A few months after the session, a self-administered survey summarizing key themes from the discussions was distributed to participants via electronic mail. In the questionnaire, summary statements were accompanied by a Likert scale, framed on a disagree -- agree continuum ([@b10-jmdh-1-29]), on a scale of 1 to 7 (with the value of 7 representing the strongest agreement). We defined "general strong agreement" with statements by a value of 5 or greater out of seven in all participants. "Opinion dissent" was reflected by agreement scores ranging from ≤3 to ≥4 among participants. "Some agreement" was defined by all agreement scores ranging from 4 to 7 among all participants. The means and standard deviations and ranges for agreement to Likert scale questions were calculated (SPSS 12.0; SPSS Inc., Chicago, IL). Completed final questionnaires were returned via electronic mail or fax as per respondent preference.

Results
=======

Description of participants and the framework of the discussions
----------------------------------------------------------------

Twenty-six participants in the workshop included experts in: health (diabetes and other diseases), methodology (epidemiology, knowledge synthesis, knowledge translation, biostatistics, and health economics), medical writing, health law, bioethics, and administration (related to a disease organization). Health experts were from multiple areas including endocrinology, medicine, primary care, ophthalmology, ethics, nursing, and nutrition. Authors of clinical practice guidelines (in diabetes and other diseases) participated. A patient representative and trainees in medicine-related specialties or ethics also participated. Representatives of the CDA as well as other disease organizations sponsoring clinical practice guidelines were included. Individuals with and without relationships with industry were included.

Qualitative theme \#1: Multifaceted potential competing interests and disclosure
--------------------------------------------------------------------------------

The existence of CIs among sponsoring organizations and authors of CPGs were recognized to be common. Some participants point out that, potential CIs could be multifaceted, including financial, academic, political, religious, cultural, personal, professional, or other organizational interests. The potential importance of nonfinancial CIs was stressed by some participants. The identified sources of financial CIs were thought to include industry, governments, third party payers, or other organizations. The optimal term for description of competing interests could not be agreed upon, with a few participants preferring the term, "duality of interest." Disclosure was used to describe the process of declaring potential CIs. The importance of disclosure of any financial CIs of sponsoring organizations or authors in the planning and development stages of CPGs was strongly asserted to be important by multiple participants. Furthermore, several participants stressed the importance of publicly disclosing CIs related to sponsoring organizations of CPGs and their authors. The lack of public disclosure of all financial CIs of sponsoring organizations and authors of CPGs was considered a threat to professional credibility and public trust in the CPG by some participants.

Qualitative theme \#2: The importance of putting the evidence first in CPG recommendations
------------------------------------------------------------------------------------------

Multiple participants asserted that CPG recommendations should be evidence-based, although it was acknowledged that some primary research evidence may be prone to CIs. The use of systematic techniques in reviewing and appraising existing evidence was encouraged by some participants. The incorporation of economic analyses in all CPGs was not thought to be feasible, because of lack of human and financial resources to carry out such analyses properly and regional variability in costs, affordability, and values. The great financial cost of producing high quality, evidence-informed CPGs was stressed my individuals involved in development of such guidelines as well as representatives of sponsoring organizations.

Qualitative theme \#3: Can competing interests be avoided in development of clinical practice guidelines?
---------------------------------------------------------------------------------------------------------

Some participants suggested that all potential financial CIs should ideally be avoided in development of CPGs. Concerns were expressed on the potential influence of relationships of physicians and the pharmaceutical industry, consciously or unconsciously, impacting recommendations. However, most participants conceded that avoidance of all financial CIs of sponsoring organizations or authors of CPGs, although ideal, may not be feasible at this time. The high need for financial and human resources in developing and disseminating high quality CPGs and the lack of peer-reviewed independent funding for such purposes, were acknowledged as important challenges. Furthermore, the contribution of knowledge and expertise from authors with known CIs, was highlighted by several participants. The scarcity of clinical content or methodologic experts without CIs was asserted. Thus, strict exclusion of all experts with CIs from CPG development could not be endorsed by most members of the group. This issue was subject to some opinion debate. However, independence of authorship and writing editing of a guideline, without any direct input of financial supporters was strongly supported by multiple participants.

Quantitative survey data
------------------------

A survey was distributed to participants several months after the workshop. In this survey, issues that were discussed at the session were summarized in the form of summary statements. The response rate to this self-administered survey was 57.7% (15/26). A summary of the responses is shown in [Table 1](#t1-jmdh-1-29){ref-type="table"}. We observed strong general agreement with statements relating to the definition of disclosure and the suggestion that CIs should be declared by sponsoring organizations and authors in the planning stage of a CPG. There was some agreement with statements suggesting that the development of CPGs is important and should not be abandoned as a knowledge translation strategy aimed at healthcare professionals. Some agreement was also observed with a suggestion that research needs to be aimed at developing effective knowledge translation strategies for dissemination and accurate representation of CPG recommendations. Respondents generally agreed that CPG recommendations should be evidence-based, without the absolute requirement of economic analyses. There was some agreement with statements suggesting that financial contributors be excluded from any aspect of writing of a CPG and that disclosure of CIs be made public. Opinion dissent was expressed with respect to the following issues: competing interests terminology, the multifaceted composition of CIs, the impact of CIs on the credibility of a CPG, and public trust, the suggestion of an advisory panel monitoring CPGs for sponsoring organizations, and the feasibility of strict avoidance of CIs.

Discussion
==========

We assembled a Canadian multidisciplinary panel and explored the concept of competing interests in development and dissemination of CPGs. Our findings highlighted the complexity and sensitivity of stakeholders to his issue. The need for transparency and disclosure of CIs of sponsoring organizations and authors of CPGs were highlighted in the qualitative and quantitative data collected. However, considerable opinion dissent was observed with respect to the issues of threshold of acceptability of CIs for authors and sponsoring organizations writing CPGs and the impact of CIs on the credibility of recommendations. Concerns were expressed on the potential influence of relationships of physicians and the pharmaceutical industry, consciously or unconsciously, impacting recommendations. It is important to acknowledge that in a prior review paper, [@b12-jmdh-1-29] reported that physician meetings with pharmaceutical representatives were associated with changes in drug formularies and prescribing behavior. However, evidence-based approaches to developing CPG recommendations were favored in CPG development by our group in hopes of minimizing bias. Yet, the use of such approaches may not necessarily safeguard CPGs from the influence of CIs, as primary research and its interpretation may be subject to potential influences of CIs. For example, it has been reported in the literature that industry sponsorship of studies is associated with pro-industry conclusions ([@b2-jmdh-1-29]). An optimal, feasible approach to minimizing the impact of CIs on CPG development could not be agreed upon in our group. In the interim, transparency of process and full disclosure of CIs were deemed essential for the credibility of CPGs

The strengths of our workshop findings are that we were able to assemble a multidisciplinary panel of experts, trainees, and a lay person from a variety of backgrounds to openly discuss a highly complex, sensitive topic that influences clinical care in diabetes care and other conditions. Furthermore, we were able to secure a closed environment, stimulating frank (and at times heated) debate among individuals with a variety of perspectives. Limitations of our study included: the lack of any strict consensus recommendations, a limited response rate to our post-workshop questionnaire, and the lack of international participants. We suspect that the relatively low response rate to our post-workshop questionnaire may be due to the sensitivity of the topic.

In terms of future research directions, it would be instructive for a multidisciplinary panel of stakeholders involved in management of other disease conditions, to explore opinions on the issue of CIs in CPGs. Also, qualitative research exploring the opinions of lay people on this issue would be valuable. In the mean time, core values including, an ethically conscious, evidence-informed, transparent approach in the development of CPGs has been emphasized in our study, in absence of any strict consensus on the threshold of acceptance (or rejection) for CIs in CPGs.

The authors are indebted to the speakers and participants of this workshop who contributed their time and opinions to this project. This project was funded by workshop support from the Canadian Institutes of Health Research (Institute of Nutrition, Metabolism, and Diabetes). The authors like to thank Ms. Lucy Montana for assisting us with the arrangements for the workshop. The authors would also like to thank Dr. Jeremy Gilbert, Shamila Kamalanathan, Dr. Siarhei Slizeuski, and Dr. Shahryar Murshed for assistance with preparing for the workshop as well as registration of participants.
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###### 

Results of an opinion survey several months after the workshop

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Statement (number of responses, maximum 15)                                                                                                                                                                                                                                                                                                                                                                    Likert scale agreement[a](#tfn1-jmdh-1-29){ref-type="table-fn"}\   Classification[b](#tfn2-jmdh-1-29){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                 Mean (Standard deviation) (Range of values)                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------
  1\. The term "competing interests" reasonably reflects various potential multifaceted interests of organizations or authors of clinical practice guidelines. (15)                                                                                                                                                                                                                                              4.9 (1.5) (2, 7)                                                   Opinion dissent

  2\. Competing interests may include financial, academic, political, cultural, religious, or other personal or organizational interests related to a topic. (15)                                                                                                                                                                                                                                                6.1 (1.3) (2, 7)                                                   Opinion dissent

  3\. Disclosure is the process of declaring competing interests. (15)                                                                                                                                                                                                                                                                                                                                           6.5 (0.6) (5, 7)                                                   General strong agreement

  4\. The presence of undisclosed, unaddressed, competing interests may threaten: a) the credibility of clinical practice guidelines among healthcare professionals and b) the public's trust. (15)                                                                                                                                                                                                              6.1 (1.3) (3, 7)                                                   Opinion dissent

  5\. Ideally, in the planning of a clinical practice guideline, a dedicated (internal or external) advisory panel should be established to evaluate, monitor, record, and ultimately disclose any competing interests related to the guideline or its authors. (15)                                                                                                                                             4.9 (1.6) (2, 7)                                                   Opinion dissent

  6\. Competing interests should be declared by sponsoring organizations and authors in the planning stage of a clinical practice guideline. (15)                                                                                                                                                                                                                                                                6.6 (0.6) (6, 7)                                                   General strong agreement

  7\. Contributing authors of a clinical practice guideline should be informed of the competing interests of the sponsoring organization as well as other coauthors in the planning stage of the guideline. (15)                                                                                                                                                                                                 6.3 (0.9) (4, 7)                                                   Some agreement

  8\. Disclosure of competing interests related to clinical practice guidelines should be made public upon release of the guideline. (14)[c](#tfn3-jmdh-1-29){ref-type="table-fn"}                                                                                                                                                                                                                               6.4 (0.9) (4, 7)                                                   Some agreement

  9\. Ideally, the presence of competing interests should be minimized for clinical practical guidelines, but complete avoidance of all potential conflicts of interests for sponsoring organizations and authors may not always be possible. (15)                                                                                                                                                               5.5 (1.8) (1, 7)                                                   Opinion dissent

  10\. If there are external financial contributors for a clinical practice guideline, such supporters should not be involved in any aspect of writing of the guideline. (15)                                                                                                                                                                                                                                    6.6 (0.9) (4, 7)                                                   Some agreement

  11\. Our group did not reach consensus on a threshold at which a contributing author has excessive competing interests precluding involvement in development of a clinical practice guideline. (15)                                                                                                                                                                                                            6.0 (0.9) (4, 7)                                                   Some agreement

  12\. Recommendations in clinical practice guidelines should be evidence-based, although it is acknowledged that some primary research evidence may prone to competing interests. (15)                                                                                                                                                                                                                          5.7 (1.0) (4, 7)                                                   Some agreement

  13\. Although the inclusion of economic analyses exploring the cost of recommendations of clinical practice guidelines may be ideal, it may not be currently feasible for all clinical practice guidelines because of lack of human and financial resources to carry out such analyses properly as well as regional variability in costs and values that might affect affordability of recommendations. (15)   5.9 (0.9) (4, 7)                                                   Some agreement

  14\. Future research is needed to develop innovative strategies to deal with competing interests in clinical practice guideline development. (15)                                                                                                                                                                                                                                                              5.6 (1.6) (3, 7)                                                   Opinion dissent

  15\. Future research is needed to develop effective knowledge translation strategies for dissemination and accurate representation of clinical practice guideline recommendations. (15)                                                                                                                                                                                                                        6.3 (0.9) (4, 7)                                                   Some agreement

  16\. The development of clinical practice guidelines is important and should not be abandoned as a knowledge translation strategy aimed at healthcare professionals. (15)                                                                                                                                                                                                                                      6.6 (1.1) (4, 7)                                                   Some agreement
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** For Likert scale questions, a score of 1 represented strong disagreement, whereas a maximal score of 7 represented the strongest agreement.

We defined "general strong agreement" with statements by a value of 5 or greater out of seven in all participants. "Opinion dissent" was reflected by agreement scores ranging from ≤3 to ≥4 among participants. "Some agreement" was defined by all agreement scores ranging from 4 to 7 among all participants.

One blank response.
